- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright startet Coverage für Upstream Bio mit "Buy" und hohem Kursziel | 4 | Investing.com Deutsch | ||
| Mi | H.C. Wainwright initiates Upstream Bio stock coverage with buy rating | 1 | Investing.com | ||
| 14.05. | Mizuho lowers Upstream Bio stock price target on operating spend tweaks | 1 | Investing.com | ||
| 14.05. | Mizuho senkt Kursziel für Upstream Bio wegen angepasster Betriebsausgaben | 1 | Investing.com Deutsch | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 13.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Upstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vor | 2 | Investing.com Deutsch | ||
| 17.04. | Upstream Bio to present verekitug data at medical conference | 1 | Investing.com | ||
| 02.04. | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| 02.04. | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com | ||
| 27.03. | Evercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herab | 1 | Investing.com Deutsch | ||
| 27.03. | Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts | 1 | Investing.com | ||
| 26.03. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 26.03. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.03. | Upstream Bio presents additional Phase 2 data for verekitug | 5 | Investing.com | ||
| 01.03. | Upstream Bio: Positive Phase-2-Daten für Verekitug, Aktie dennoch unter Druck | 1 | Investing.com Deutsch | ||
| 01.03. | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | 257 | GlobeNewswire (Europe) | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen | |
| 26.02. | Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 13.02. | Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | 20 | Benzinga.com | ||
| 11.02. | Upstream Bio Shares Plunge 52% Despite Positive Phase 2 Asthma Data | 5 | RTTNews |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
Das Unternehmen UPSTREAM BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,07 % bei einem Aktienkurs von 7,045 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.